FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555542997> ?p ?o ?g. }

• W2555542997 abstract "Abstract Abstract 1956 Poster Board I-979 Background: Fluoro-deoxy-glucose positron emission tomography (FDG-PET) is a required staging study for diffuse large B-cell lymphoma and Hodgkin lymphoma. Numerous studies have demonstrated that FDG-PET performed after one to four cycles of multiagent chemotherapy (interim restaging) is predictive of outcome, with relapse rates much higher in patients with positive FDG-PET scans at interim restaging. The prognostic role of FDG-PET in T-cell lymphoma however is unclear and has yet to be well defined. Small retrospective studies have demonstrated FDG-PET avidity of T-cell lymphoma. Our experience confirms that the great majority of patients with mature T or NK lymphomas have FDG-PET avid disease. We hypothesized that the interim FDG-PET (int FDG-PET) may have prognostic importance in patients with T-cell lymphomas as they do in diffuse large B-cell lymphoma and Hodgkin lymphoma. Methods: We reviewed our T-cell lymphoma database to identify patients with mature T or NK lymphomas who had FDG-PET scans as part of complete staging at initial diagnosis as well as repeat PET imaging as part of restaging. Inclusion criteria required FDG-PET avid disease at baseline and treatment administered with curative intent. Results: We reviewed fifty four patients who met the above criteria. Histologies were as follows: peripheral T-cell lymphoma NOS (N=18), angioimmunoblastic T-cell lymphoma (N=5), anaplastic large cell lymphoma ALK-1- (N=15), anaplastic large cell lymphoma ALK-1+ (N=3), and other subtypes (N=13). Patients received a variety of initial chemotherapy regimens including CHOP (N=18), EPOCH (N=6), CHOP/ICE (N=20) or other treatments provided with curative intent. Twenty two patients were consolidated with high dose therapy and either autologous (N=18), or allogeneic (N=4) SCT. Fifty nine percent were PET negative at interim restaging (32/54), 7.4% were positive (4/54), 22 % were not available (12/54), and 11% had equivocal scans (6/54). Median follow up was 17 months. Median PFS for the entire group was 15 months. Median OS for the entire group was 40 months. The median OS of patients with negative int FDG-PET has not been reached, compared to the OS of patients with positive int FDG-PET of 10.2 months (p<.001). Patients with equivocal int FDG-PET had a median OS of 62 months, which was statistically superior to patients with positive int FDG-PET (p=.02). There was no significant difference in median OS in patients with negative versus equivocal int FDG-PET. Similar to what was observed in OS, the median PFS of patients with negative int FDG-PET has not yet been reached, compared to the PFS of patients with a positive int FDG-PET of 4.8 months (p=<.001). Patients with equivocal int FDG-PET had a statistically improved PFS of 16 months when compared to those with a positive int FDG-PET (p<.01). Patients with equivocal int FDG-PET had similar outcomes to patients with a negative int FDG-PET, and superior to those with a positive int FDG-PET, whose results were very poor. Conclusions: In this dataset, interim PET scans are strongly predictive of outcome. Patients with negative int FDG-PET enjoyed significantly longer remissions and better overall survival. Patients with negative int FDG-PET were more likely to receive consolidative therapy, which may contribute to their superior outcomes. This may be a potentially confounding factor. Nonetheless, achievement of a negative int FDG-PET appears to be a reliable predictor of outcome in patients with T-cell lymphomas and may have similar prognostic importance in these patients as they do in diffuse large B-cell lymphoma and Hodgkin lymphoma. It is reasonable to consider int FDG-PET in the restaging of patients with T-cell lymphomas. Disclosures: Zelenetz: Millenium Advisory board: Membership on an entity's Board of Directors or advisory committees. Horwitz:Allos Therapeutics, Inc: Consultancy, Research Funding." @default.
• W2555542997 created "2016-11-30" @default.
• W2555542997 creator A5001102192 @default.
• W2555542997 creator A5061964017 @default.
• W2555542997 creator A5064738578 @default.
• W2555542997 creator A5069406522 @default.
• W2555542997 date "2009-11-20" @default.
• W2555542997 modified "2023-09-30" @default.
• W2555542997 title "Negative Interim FDG-PET Scan Is Predictive of Superior Outcome in T Cell Lymphoma." @default.
• W2555542997 doi "https://doi.org/10.1182/blood.v114.22.1956.1956" @default.
• W2555542997 hasPublicationYear "2009" @default.
• W2555542997 type Work @default.
• W2555542997 sameAs 2555542997 @default.
• W2555542997 citedByCount "1" @default.
• W2555542997 countsByYear W25555429972020 @default.
• W2555542997 crossrefType "journal-article" @default.
• W2555542997 hasAuthorship W2555542997A5001102192 @default.
• W2555542997 hasAuthorship W2555542997A5061964017 @default.
• W2555542997 hasAuthorship W2555542997A5064738578 @default.
• W2555542997 hasAuthorship W2555542997A5069406522 @default.
• W2555542997 hasConcept C126322002 @default.
• W2555542997 hasConcept C143998085 @default.
• W2555542997 hasConcept C166957645 @default.
• W2555542997 hasConcept C2775842073 @default.
• W2555542997 hasConcept C2776957806 @default.
• W2555542997 hasConcept C2777589544 @default.
• W2555542997 hasConcept C2777872185 @default.
• W2555542997 hasConcept C2779338263 @default.
• W2555542997 hasConcept C2989005 @default.
• W2555542997 hasConcept C71924100 @default.
• W2555542997 hasConcept C95457728 @default.
• W2555542997 hasConceptScore W2555542997C126322002 @default.
• W2555542997 hasConceptScore W2555542997C143998085 @default.
• W2555542997 hasConceptScore W2555542997C166957645 @default.
• W2555542997 hasConceptScore W2555542997C2775842073 @default.
• W2555542997 hasConceptScore W2555542997C2776957806 @default.
• W2555542997 hasConceptScore W2555542997C2777589544 @default.
• W2555542997 hasConceptScore W2555542997C2777872185 @default.
• W2555542997 hasConceptScore W2555542997C2779338263 @default.
• W2555542997 hasConceptScore W2555542997C2989005 @default.
• W2555542997 hasConceptScore W2555542997C71924100 @default.
• W2555542997 hasConceptScore W2555542997C95457728 @default.
• W2555542997 hasLocation W25555429971 @default.
• W2555542997 hasOpenAccess W2555542997 @default.
• W2555542997 hasPrimaryLocation W25555429971 @default.
• W2555542997 hasRelatedWork W1972371407 @default.
• W2555542997 hasRelatedWork W2002509450 @default.
• W2555542997 hasRelatedWork W2003464096 @default.
• W2555542997 hasRelatedWork W2096140967 @default.
• W2555542997 hasRelatedWork W2524197916 @default.
• W2555542997 hasRelatedWork W2555885038 @default.
• W2555542997 hasRelatedWork W2566124540 @default.
• W2555542997 hasRelatedWork W2580246444 @default.
• W2555542997 hasRelatedWork W2584611019 @default.
• W2555542997 hasRelatedWork W2586086072 @default.
• W2555542997 hasRelatedWork W2588153269 @default.
• W2555542997 hasRelatedWork W2589886857 @default.
• W2555542997 hasRelatedWork W2678050653 @default.
• W2555542997 hasRelatedWork W2730939471 @default.
• W2555542997 hasRelatedWork W2753912481 @default.
• W2555542997 hasRelatedWork W2901931286 @default.
• W2555542997 hasRelatedWork W2978428646 @default.
• W2555542997 hasRelatedWork W2978502618 @default.
• W2555542997 hasRelatedWork W334673566 @default.
• W2555542997 hasRelatedWork W1649161558 @default.
• W2555542997 isParatext "false" @default.
• W2555542997 isRetracted "false" @default.
• W2555542997 magId "2555542997" @default.
• W2555542997 workType "article" @default.